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Abstract
Introduction: The aim of this study was to examine the serum levels of S100 proteins and to evaluate their role in
patients with recent-onset rheumatoid arthritis (RA).
Methods: Serum levels of S100A8/9 and S100A12 were analysed in 43 patients with recent-onset RA, both before
and three months after the initiation of conventional treatment, as well as in 32 healthy individuals. Disease activity
was assessed based on serum levels of C-reactive protein (CRP), the Disease Activity Score for 28 joints (DAS28)
and the total number of swollen joints count for 66 joints (SJC).
Results: The levels of serum S100A8/9 and S100A12 were significantly higher in patients with recent-onset RA
compared to the levels in healthy individuals (P < 0.0001) and normalised after three months of treatment. Using
age- and sex-adjusted analysis, S100A8/9 levels were correlated with CRP (r = 0.439, P < 0.01), DAS28 (r = 0.501, P
= 0.002) and SJC (r = 0.443, P = 0.007), while S100A12 was less significantly correlated with these parameters.
Higher levels of S100A8/9 at baseline predicted improvement in the levels of CRP and SJC over time. Moreover,
decreases in serum S100A8/9 were associated with decreased serum levels of CRP (r = 0.459, P = 0.005) and
improvements in SJC (r = 0.459, P = 0.005). In multiple linear regression analyses, decreases in S100A8/9 but not
CRP were significant predictors for improvements in SJC (P = 0.001).
Conclusions: This study is the first to show normalisation of elevated S100 proteins in patients with recent-onset
RA after the initiation of conventional treatment. Therefore, S100A8/9 might potentially be a predictive marker for
improvement in the total number of swollen joints in patients in the early phase of RA.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
autoimmune disease characterised by synovitis and joint
destruction in which the infiltration of inflammatory
cells, the activation of synovial fibroblasts and the pro-
duction of a wide range of inflammatory mediators play
significant roles [1,2]. However, the exact pathological
processes involved in the initiation of RA remain
incompletely understood. Very early RA is suggested to
represent an immunopathologically distinct phase of the
disease in which a “window of opportunity” for early
drug intervention with the potential to prevent joint
damage may exist [3]. Recent studies have shown that
the development of established RA in patients in the
early stages of the disease can be predicted by using
clinical and serological measures [4-6]. Therefore, a bet-
ter understanding of the pathological mechanisms and
biomarkers during this early phase would be an impor-
tant way to determine possible new therapeutic targets
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individual patients.
S100 calcium-binding proteins are multifunctional
proteins that are implicated in the regulation of a variety
of cellular activities [7]. The most familiar S100 proteins,
myeloid-related proteins S100A8/9 (calprotectin) and
S100A12 (calgranulin C), have recently been proposed
as “alarmins,” which are the endogenous molecules that
signal the early phase of tissue and cell damage [8]. The
S100 proteins are expressed predominantly by neutro-
phils, monocytes and activated macrophages, and
increased S100 levels have been demonstrated in several
inflammatory diseases [9]. S100A8/9 and S100A12 are
increased locally at sites of inflammation as well as in
the circulation of patients with RA [10-13]. Moreover, a
tight correlation between S100 proteins and laboratory
and clinical markers of disease activity has been demon-
strated in patients with different arthritides [13-16]. In
addition, S100A8/9 and S100A12 were shown to be
decreased locally in synovial tissue as well as in the
blood in response to different anti-inflammatory thera-
pies, including TNFa inhibitors, and they were upregu-
lated weeks before relapse became clinically apparent in
patients with previously well-controlled disease [16-19].
S100A8/9 was associated with measures of joint damage
in one cross-sectional study [20]. More importantly,
longitudinal data demonstrated that S100A8/9 was a
good prognostic biomarker for long-term radiographic
joint progression in patients with established RA [21].
However, S100 proteins have not yet been studied in
treatment-naïve RA patients. Therefore, we explored the
following: (1) the levels of S100 proteins in patients with
recent-onset RA, (2) the effect of conventional treatment
on the levels of serum S100 proteins, (3) the association
between S100 proteins and disease activity and (4) a
potential role of S100 proteins as surrogate predictive
markers in a short-term longitudinal study.
Materials and methods
Patients and clinical examination
A total of 43 patients with recent-onset RA were
included in this study. Inclusion criteria were as follows:
(1) age > 18 years, (2) fulfilment of the American Col-
lege of Rheumatology/European League Against Rheu-
matism (EULAR) 2010 classification criteria for RA at
baseline [22] and (3) symptom duration of less than six
months. None of the patients had been receiving dis-
ease-modifying antirheumatic drugs (DMARDs) or glu-
cocorticoids (GCs) at baseline. After the initiation of
conventional treatment, patients were prospectively fol-
lowed for three months. Disease activity was assessed
based on the Disease Activity Score for 28 joints
(DAS28) using the number of swollen and tender joints,
erythrocyte sedimentation rate (ESR) and the patient’s
global assessment of activity on a visual analogue scale
(VAS) [23]. Swollen joints count for 66 joints (SJC) was
also evaluated. The clinical response was defined by the
EULAR response criteria [24]. Patients were charac-
terised as follows: good responders had a DAS28 ≤ 3.2
plus a > 1.2 decrease in DAS28, and moderate respon-
ders were defined as having (1) DAS28 ≤3.2 plus a > 0.6
and ≤1.2 decrease in DAS28, (2) DAS28 ≤ 5.1 > 3.2 plus
a>0 . 6d e c r e a s ei nD A S 2 8o r( 3 )D A S 2 8>5 . 1p l u sa>
1.2 decrease in DAS28. Nonresponders were defined as
having a < 0.6 decrease in DAS28 or a DAS28 > 5.1
plus a ≤1.2 decrease in DAS28. The control group con-
sisted of 32 healthy individuals. The study was approved
by the local ethics committee, and informed consent
was obtained from all patients prior to initiation of the
protocol.
ELISA
Blood samples were collected from all patients at base-
line (before therapy) and three months after the start of
therapy. Serum samples were immediately centrifuged
a n ds t o r e da t- 8 0 ° Cu n t i la n a l y s i s .T h el e v e l so fs e r u m
S100A8/9 (Bühlmann Laboratories AG, Schönenbuch,
Switzerland) and S100A12 (CycLex Co., Ltd., Nagano,
Japan) were measured by using commercially available
ELISA kits according to the manufacturers’ protocols.
Absorbance was detected using the Sunrise ELISA
reader (Tecan Group Ltd., Salzburg, Austria) with 450
nm as the primary wavelength. Interassay and intraassay
reliability of the S100A8/9 assays were 5.3% and 6.2%,
respectively. Interassay and intraassay reliability of the
S100A12 assays were 3.3% and 3.4%, respectively. The
detection limits were 3 ng/mL for the S100A8/9 assay
and 56 pg/mL for the S100A12 assay. C-reactive protein
(CRP) was measured using nephelometry. Analyses of
serum anticyclic citrullinated peptide antibodies (anti-
CCP) and immunoglobulin M rheumatoid factor (IgM-
R F )w e r ec a r r i e do u tu s i n gs t a n d a r dE L I S Ak i t s( T e s t
Line s.r.o., Brno, Czech Republic).
Statistical analyses
The concentrations of S100 proteins are expressed as
means ± SEM. A Kolmogorov-Smirnov test of normality
was performed for all variables and their difference
scores. Pearson’s product-moment correlation coeffi-
cients and Spearman’s rank correlation coefficients were
used in cases of normal and non-normal variables,
respectively. When comparing patients and controls, the
independent samples t-test was used for normal vari-
ables and the Mann-Whitney U test was used as a non-
parametric alternative. Two-way analysis of variance
with repeated measures (time × groups) was conducted
to determine the differences between groups of patients
sorted on the basis of the level of disease activity. In
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formed for differences in scores on the DAS28 and total
SJC, and appropriate predictors were chosen using a
backward stepwise elimination method. For all statistical
evaluations, P values below 0.05 were considered to be
statistically significant. Statistical analyses were per-
formed using SPSS version 17 software (SPSS Inc., Chi-
cago, IL, USA).
Results
Table 1 shows the baseline characteristics of the patients
and healthy controls. Overall, three patients with recent-
onset RA had erosions at baseline. Prior to treatment,
22 patients had highly active disease (mean DAS28 >
5.1), 19 patients had moderate disease activity (mean 3.2
<D A S 2 8≤ 5.1) and 2 patients had low disease activity
(mean 2.6 ≤ DAS28 < 3.2). Initially, DMARD treatment
was started in 42 patients. Thirty-five patients received
methotrexate (mean dose at month 3: 14.86 mg/week;
range: 7.5 to 20 mg/week), six received sulphasalazine,
one received leflunomide and thirty-eight received GCs
(prednisone or equivalent; initial mean daily dose: 8.9
mg/day; range: 2.5 to 20 mg/day). After three months of
treatment, a significant reduction in disease activity was
observed (mean DAS28: 5.3 ± 1.5 to 2.8 ± 1.3; mean
SJC: 10.0 ± 9.2 to 1.7 ± 3.6; mean CRP: 16.2 ± 19.8 to
4.2 ± 5.8; P < 0.0001 for all comparisons). Thirty-nine
patients (90.7%) achieved good or moderate improve-
ment, and eighteen (41.9%) reached remission according
to the EULAR response criteria [24].
S100 proteins and disease activity at baseline
The levels of serum S100A8/9 correlated significantly
with S100A12 at baseline (r =0 . 8 4 5 ,P < 0.0001), an
association that became even stronger when adjusted for
age and sex (r =0 . 9 0 1 ,P < 0.0001). This positive corre-
lation remained significant three months after the start
of the treatment. The levels of S100 proteins were not
affected by age or gender (data not shown).
In univariate analysis, the serum levels of S100A8/9
correlated positively with the levels of CRP (r = 0.553, P
< 0.0001), DAS28 (r = 0.469, P < 0.01) and SJC (r =
0.363, P < 0.05) at baseline (Figures 1A through 1C).
When adjusted for age and sex, these correlations
remained significant for CRP (r = 0.439, P <0 . 0 1 )a n d
became stronger for DAS28 (r = 0.501, P = 0.002) and
SJC (r =0 . 4 4 3 ,P = 0.007). Similarly, the levels of
S100A12 correlated positively with the levels of CRP (r
= 0.350, P <0 . 0 5 )a n dD A S 2 8( r = 0.313, P <0 . 0 5 ) ,
although there was only a trend for the correlation
between the levels of S100A12 and SJC (r =0 . 2 9 2 ,P =
0.057) at baseline (Figures 1D through 1F). When
adjusted for age and sex, these correlations were lost for
CRP (r = 0.288, P = 0.083) but remained significant for
DAS28 (r = 0.354, P = 0.034) and became significant for
SJC (r = 0.345, P = 0.039). Furthermore, neither
S100A8/9 nor S100A12 was associated with IgM-RF (r
= -0.056, P = 0.727, and r =0 . 1 7 0 ,P = 0.289, respec-
tively) or anti-CCP levels (r = -0.195, P =0 . 2 1 0 ,a n dr =
-0.044, P = 0.778, respectively).
Effect of conventional treatment on the levels of S100
proteins
The levels of serum S100A8/9 (mean 5.99 ± 0.88 μg/mL
vs. 1.92 ± 1.16 μg/mL; P < 0.0001) and S100A12 (mean
0.30 ± 0.04 μg/mL vs. 0.13 ± 0.11 μg/mL; P < 0.0001)
were significantly higher in patients with recent-onset
RA compared with healthy controls, and these levels
essentially normalised after three months of treatment
(mean S100A8/9: 5.99 ± 0.88 μg/mL to 2.49 ± 0.21 μg/
mL; P < 0.0001; mean S100A12: 0.30 ± 0.04 μg/mL to
0.13 ± 0.01 μg/mL; P < 0.0001) (Figure 2). Importantly,
after three months, the levels of S100A8/9 but not
S100A12 were significantly lower in patients who had
achieved remission compared with those who showed
moderate or high disease activity (mean S100A8/9: 2.15
±1 . 1 1μg/mL vs. 3.37 ± 1.34 μg/mL; P = 0.043). We
found significantly higher levels of baseline S100A8/9
and S100A12 concentrations in patients with active dis-
ease compared with those with moderate disease activity
(mean S100A8/9: 7.96 ± 1.52 μg/mL vs. 4.20 ± 0.63 μg/
mL, P = 0.004, and mean S100A12: 0.37 ± 0.07 μg/mL
vs. 0.24 ± 0.04 μg/mL, P = 0.035, respectively). S100A8/
9 and S100A12 serum levels significantly decreased over
time, particularly in patients with active disease (mean
S100A8/9: 7.96 ± 1.52 μg/mL to 2.81 ± 0.31 μg/mL and
mean S100A12: 0.37 ± 0.07 μg/mL to 0.14 ± 0.02 μg/
mL; P < 0.0001 for both comparisons). However, in
patients with moderate disease activity, a modest
Table 1 Baseline characteristics of patients with recent-
onset RA and healthy controls
a
Characteristics Recent-onset
RA
(n = 43)
Healthy
controls
(n = 32)
Gender, F/M 30/13 11/21
Mean age, years (±SD) 50.90 ± 16.40 43.97 ± 15.4
Mean CRP, mg/L (±SD) 16.20 ± 20
Mean ESR, mm/1
st hour (±SD) 34.20 ± 23.72
Mean SJC out of 66 (±SD) 10.00 ± 9.28
Mean DAS28 score (±SD) 5.31 ± 1.51
RF positivity, n (%) 32 (74.4%)
Anti-CCP positivity, n (%) 22 (51.2%)
DMARDs/GCs, number of
patients
42/35
aAnti-CCP, anticyclic citrullinated peptide antibody; CRP, C-reactive protein;
DAS28, Disease Activity Score for 28 joints; DMARDs, disease-modifying
antirheumatic drugs; RA, rheumatoid arthritis; ESR, erythrocyte sedimentation
rate; F, female; GCs, glucocorticoids; M, male; RF, rheumatoid factor.
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Page 3 of 9Figure 1 Scatterplots showing correlations between serum levels of (A) through (C) S100A8/9 and (D) through (F) S100A12 and
disease activity measures in patients with recent-onset rheumatoid arthritis (RA). CRP, C-reactive protein; DAS28, Disease Activity Score for
28 joints; SJC, swollen joint count for 66 joints.
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Page 4 of 9decrease in S100A12 (mean 0.24 ± 0.04 μg/mL to 0.13 ±
0.02 μg/mL; P = 0.046) and a statistically insignificant
decrease in S100A8/9 (mean 4.20 ± 0.63 μg/mL to 2.29
±0 . 2 6μg/mL; P =0 . 1 1 2 )w a so b s e r v e d .T h el e v e l so f
S100 proteins were not affected by different dosages of
GCs and/or methotrexate.
Predictive role of S100 proteins
Higher levels of S100A8/9 at baseline predicted an
improvement in the level of CRP (r = -0.397, P =0 . 0 1 )
and in SJC (r = -0.369, P < 0.05), but not in DAS28 (r =
-0.279, P = 0.07). When adjusted for age and sex, the
correlations of S100A8/9 with changes in the levels of
CRP (r = -0.423, P =0 . 0 1 )a n dc h a n g e si nS J C( r =
-0.423, P = 0.01) became stronger. The levels of
S100A12 at baseline were predictive of the change in
SJC (r = -0.376, P < 0.05), but not in the level of CRP (r
= -0.212, P = 0.184) or in DAS28 (r = -0.282, P =0 . 0 7 ) ,
which remained significant when adjusted for age and
sex for baseline S100A12 and changes in SJC (r =
-0.360, P = 0.031).
Furthermore, we found that changes in serum
S100A8/9 positively correlated with changes in serum
levels of CRP (r = 0.476, P = 0.002), changes in DAS28
(r = 0.390, P = 0.01) and changes in SJC (r =0 . 5 3 9 ,P <
0.001) (Figures 3A through 3C). When adjusted for age
and sex, the correlations remained significant for
changes in CRP (r = 0.459, P = 0.005) and changes in
SJC (r = 0.459, P = 0.005), but not for changes in
DAS28 (r = 0.258, P =0 . 1 2 9 ) .H o w e v e r ,c h a n g e si n
serum S100A12 correlated with changes in SJC (r =
0.379, P <0 . 0 5 ) ,b u tn o tw i t hc h a n g e si ns e r u mC R P( r
= 0.257, P = 0.105) or changes in DAS28 (r = 0.271, P =
0.079) (Figures 3D through 3F). Age and sex-adjusted
changes in serum S100A12 also correlated only with
changes in SJC (r = 0.343, P = 0.04).
Multiple linear regression analysis showed that base-
line DAS28 and changes in DAS28 were easier to pre-
dict using CRP and S100A8/9 than baseline SJC and
changes in SJC (Tables 2 and 3). The levels of CRP
were more important predictors of DAS28 at baseline
than the levels of S100A8/9, which were only marginally
acceptable as predictors of baseline DAS28 (P = 0.052)
(Table 2). The levels of both CRP and S100A8/9 at
baseline were only weak predictors of the baseline SJC
(P = 0.045 and P = 0.051, respectively). Interestingly, the
change in S100A8/9 levels was significantly associated
with the change in SJC over time (P = 0.001) (Table 3).
It can thus be suggested that decreases in serum
S100A8/9 over time predict improvements in the num-
ber of affected joints.
Discussion
To the best of our knowledge, this study is the first to
show elevated serum levels of S100 proteins in patients
with recent-onset DMARD/GC-naïve RA, the associa-
tion between S100 proteins and disease activity and nor-
malisation of S100A8/9 in patients who achieve
remission after conventional treatment. Furthermore, we
have demonstrated that decreases in S100A8/9 levels are
associated with clinical improvement in the number of
affected joints.
S100 proteins were previously found to be upregulated
in the inflamed synovial tissue, synovial fluid and blood
of patients with established RA [10-13]. However, in this
study, we have shown for the first time significantly
increased serum levels of both S100A8/9 and S100A12
proteins in patients with recent-onset RA who had not
Figure 2 Serum levels of (A) S100A8/9 and (B) S100A12 proteins were increased in patients with recent-onset rheumatoid arthritis
(RA) and normalised after three months of conventional treatment. Dots represent healthy controls, squares stand for recent onset RA
patients at baseline and triangles represent recent onset RA patients after 3 months treatment.
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Page 5 of 9Figure 3 Scatterplots showing correlations of changes in (A) through (C) S100A8/9 and (D) through (F) S100A12 levels during
treatment with changes in disease activity measures in patients with recent-onset rheumatoid arthritis. CRP, C-reactive protein; DAS28,
Disease Activity Score for 28 joints; SJC, swollen joint count out of 66.
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consistent with previous reports showing elevated circu-
lating S100 proteins in patients with previously estab-
lished disease [10-13]. However, compared to previous
studies [19,25], the levels of S100A8/9 measured in our
study were higher, which can be explained by the use of
various antibodies to detect different epitopes in differ-
ent ELISAs. In our commercial assay, an antibody
detecting an epitope which is dependent on S100A8/
S100A9 heterocomplex formation and calcium binding
was used. Nevertheless, this did not affect the compara-
tive study in general. It has previously been demon-
strated that the S100A8/9 and S100A12 proteins show
decreased levels in the peripheral circulation in response
to different anti-inflammatory therapies [16,17]. Consis-
t e n tw i t hs u c hf i n d i n g s ,w eh a v es h o w ni nt h ep r e s e n t
study that the conventional treatment of patients with
DMARD/GC-naïve early-stage RA reduces serum levels
of S100 proteins to the normal levels found in healthy
individuals. As expected, patients with very active dis-
ease at baseline had higher levels of S100A8/9 and
S100A12 proteins that decreased more significantly as
the disease improved than did patients with moderate
disease activity. Furthermore, an association between
both serum S100 proteins in patients with recent-onset
RA is in agreement with previous reports on established
RA [26,27], which have indicated that S100A8/9 and
S100A12 proteins may be coregulated early in the dis-
ease process.
In agreement with previous reports on established RA
[10-13,15,20,21], we found an association of both
S100A8/9 and S100A12 proteins with laboratory and
clinical markers of disease activity in patients with
recent-onset RA. Interestingly, this association was more
pronounced for S100A8/9 than for S100A12. Higher
baseline levels of S100A8/9 predicted decreased CRP
levels and improvements in the total number of swollen
joints over time. Moreover, decreases in S100A8/9 levels
were directly related to clinical and laboratory improve-
ments over time. Multivariate regression analysis
revealed that baseline S100A8/9 values were not more
predictive of disease activity than traditional biomarkers
such as CRP and that they were only marginally accep-
table as predictors of baseline disease activity. However,
both CRP and S100A8/9 levels were found to be weak
predictors for the baseline number of swollen joints.
Interestingly, however, changes in the levels of S100A8/
9, but not CRP, were associated with changes in the
total number of swollen joints over time. It is evident
that S100 proteins are extensively produced by activated
immune cells of the synovial membrane and synovial
fluid in affected joints and pass into the blood circula-
tion [12,13]. Our data support the hypothesis that
S100A8/9 protein represents a suitable marker that pro-
vides important information about the extent of local
inflammation in affected joints, as shown by the strong
associations between the decrease in S100A8/9 levels
and improvements in swollen joint counts. Although
researchers in some studies have found an association
between S100 proteins and autoantibodies in patients
with RA [15,20,25], we have not confirmed these data,
which may be explained by a stronger association with
disease activity than with the autoimmune response in
the early phase of recent-onset RA. S100A8/9 protein
has recently been demonstrated to predict 10-year
radiographic progression in patients with established RA
[21]. Although our study was not sufficiently long to
assess the effect of changes in S100A8/9 levels on the
radiographic progression of early RA, it can be sug-
gested that a decrease in serum levels of S100A8/9 over
Table 2 Multiple linear regression models for initial DAS28 and changes in DAS28
a
Initial DAS28 (n = 43; r
2 = 0.422; F = 16.355; P < 0.000)
b ΔDAS28 (n = 41; r
2 = 0.349, F = 11.727; P < 0.000)
c
Variables Parameter estimate SEM t-value P value Variable Parameter estimate SEM t-value P value
Intercept 4.351 0.246 17.662 0.000 Intercept -2.117 0.277 -7.649 0.000
Initial CRP 0.037 0.010 3.619 0.001 Initial CRP 0.080 0.038 2.124 0.040
Initial S100A8/9 0.000 0.000 2.007 0.052 ΔCRP 0.136 0.042 3.248 0.002
aDAS28, Disease Activity Score for 28 joints; SEM, standard error of the mean; CRP, C-reactive protein. r
2 values are adjusted.
bExcluded predictors are age and
initial S100A12.
cExcluded predictors are age, initial S100A12, initial S100A8/9, ΔS100A12 and ΔS100A8/9.
Table 3 Multiple linear regression models for initial total SJCs and change in SJCs
a
Initial SJCs (n = 43, r
2 = 0.260, F = 8.360; P = 0.001)
b ΔSJCs (n = 41, r
2 = 0.245, F = 13.974; P = 0.001)
c
Variables Parameter estimate SEM t-value P value Variable Parameter estimate SEM t-value P value
Intercept 5.093 1.712 2.975 0.005 Intercept -5.192 1.148 -3.500 0.001
Initial CRP 0.147 0.071 2.067 0.045 ΔS100A8/9 0.001 0.000 3.738 0.001
Initial S100A8/9 0.001 0.000 2.010 0.051 - - - - -
aSJCs, swollen joint counts; SEM, standard error of the mean; CRP, C-reactive protein. r
2 values are adjusted.
bExcluded predictors are age and initial S100A12.
cExcluded predictors are age, initial S100A12, initial S100A8/9, initial CRP, ΔS100A12 and ΔCRP.
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ber of affected joints, might be associated with inhibi-
tion of further structural joint damage. This remains to
be determined in future studies.
Conclusions
In summary, our data show elevated serum levels of
S100 proteins at the onset of RA and a normalisation of
S100A8/9 levels in patients who achieved remission
shortly after the initiation of conventional treatment.
Furthermore, decreases in S100A8/9 rather than CRP
levels were associated with improvements in the total
number of swollen joints over time. Further studies are
needed to determine whether S100A8/9 levels may have
a predictive value for further structural damage in
patients with recent-onset RA.
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